Recombinant Human VEGF (165aa) | Z100895

abm | Recombinant Human VEGF (165aa) | Z100895

VEGF is a homodimeric glycoprotein that is actively involved in angiogenesis, vasculogenesis and endothelial cell growth. Owing to alternative splicing of the mRNA, VEGF occurs in several molecular variants of 121, 162, 145, 148, 165, 183, 189 and 206 amino acids. The various isoforms of VEGF differ in biological properties such as; (a) the receptors they recognize and (b) their interaction with heparan sulfate proteoglycans. VEGF-121 and VEGF-165 are soluble secreted forms of the factor while VEGF-189 and VEGF-206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. VEGF-165 is the most common variant in most tissues and one with heparin binding properties. Recombinant VEGF-165aa is a non-glycosylated, disulfide linked homodimer.

Functions:

The ED50 as determined by the dose-dependent proliferation of human umbilical vein endothelial cells was found to be <0.1ng/ml.

Organism:

Human

Source:

E. coli

Alias:

Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGFA, VEGF-165aa
Recombinant Human Vascular Endothelial Growth Factor 165AA (VEGFA)

Gene Symbol:

VEGFA

Gene ID:

7422

Accession:

P15692

Formulation:

Lyophilized from 0.2 μm filtered solution in sodium phosphate and NaCl (pH 6.5)

Solubility:

A quick spin of the vial followed by reconstitution in distilled water to a concentration no less than 0.1 mg/mL. This solution can then be diluted into other buffers.

Appearance:

Lyophilized Powder

Molecular Weight (kDa):

19

Molecular Weight 2 (kDA):

N/A

Molecular Weight 3 (kDA):

N/A

Purity:

>95% as determined by SDS-PAGE

Concentration:

<1.0 EU/μg of recombinant protein as determined by the LAL method

Shipping Condition :

Ambient Temperature

Storage Condition:

The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.